This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.
Key Takeaways
Key Takeaways
- Worldwide, the publisher estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10–19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
- In this demographic group, the publisher forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026.
- Edgemont’s Fluoxetine Tablets, Eli Lilly’s Prozac, and Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
- There are only two industry-sponsored drugs in active clinical development for eating disorders, both of which are in Phase II. Therapies in active clinical development for eating disorders target hypocretin/orexin receptor and ghrelin receptor. These therapies are being tested as oral and subcutaneous formulations.
- The overall likelihood of approval of a Phase I eating disorders asset is 8.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 5.8 years from Phase I to approval, compared to 9.3 years in the overall psychiatry space.
- All of the clinical trials for eating disorders have been in Phase III. The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major European markets.
- Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with three trials.
- Takeda leads industry sponsors with the highest number of Phase III clinical trials for eating disorders, followed by Johnson & Johnson
Table of Contents
OVERVIEWKEY TAKEAWAYSEPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSPROBABILITY OF SUCCESSREVENUE OPPORTUNITYBIBLIOGRAPHYAPPENDIX
DISEASE BACKGROUND
TREATMENT
CLINICAL TRIAL LANDSCAPE
LIST OF FIGURES
LIST OF TABLES